Agonist– tag –
-
Rani Therapeutics Achieves 84% Bioavailability for Oral Ustekinumab Biosimilar; Oral GLP-1s Drive Commercial Success in Biopharma Delivery
Drug Delivery Leader USA Overview The successful FDA approval and commercial launch of oral semaglutide (Wegovy) and orforglipron highlight the critical role of oral delivery in chronic disease management, significantly improving patient... -
Oral GLP-1 Receptor Agonists Foundayo (Orforglipron) and Wegovy Pill (Oral Semaglutide) Demonstrate Average Weight Loss of 12.4% and 16.6% Respectively by 2026
PrivateDoc® Unknown Overview By 2026, two oral GLP-1 receptor agonists, Foundayo (orforglipron) and Wegovy pill (oral semaglutide), are approved for weight management in the UK. Foundayo, a small-molecule non-peptide, can be taken with o... -
Eli Lilly’s Foundayo® (Orforglipron) Receives FDA Approval as First Oral Non-Peptide GLP-1 Receptor Agonist, Demonstrates Significant Weight Loss and Cardiometabolic Improvement
Obesity Medicine Review Unknown Overview Eli Lilly's Orforglipron, branded as Foundayo®, has received FDA approval as the latest oral GLP-1 receptor agonist. Distinguishing itself from oral semaglutide (Wegovy®) as a small-molecule, non-... -
Gan & Lee Pharmaceuticals Initiates Phase I Trial for Once-Weekly Oral GLP-1 Peptide GZC8072 in China, Targeting Obesity and Type 2 Diabetes
AllSci China Overview Gan & Lee Pharmaceuticals Co., Ltd. has commenced its Phase I clinical trial for GZC8072, a novel once-weekly oral GLP-1 receptor peptide agonist, targeting type 2 diabetes and weight management in overweight or... -
Eli Lilly’s Oral GLP-1 Agonist Orforglipron Shows Promising Weight Loss and Safety in Phase 2 Trials, Rivaling Injectables
Endocrinology Today USA Overview Eli Lilly's investigational oral GLP-1 receptor agonist, Orforglipron, demonstrated weight loss comparable to some injectable GLP-1s in Phase 2 trials for obesity and type 2 diabetes. As a non-peptide sma... -
Structure Therapeutics’ Oral GLP-1 Aleniglipron Achieves 16.3% Weight Reduction in Phase 2, Advances to Phase 3 Amidst Robust Obesity Pipeline
Becker's Hospital Review Unknown Overview A pipeline update on 13 experimental weight-loss drugs highlights Structure Therapeutics' oral GLP-1 agent, Aleniglipron, which demonstrated a remarkable 16.3% placebo-adjusted weight reduction i... -
Widespread GLP-1 Agonist Use Reduces US Adult Obesity Rate by 2% (2022-2025); WHO Recognizes Obesity as Chronic Disease
LinkedIn USA Overview Widespread adoption of GLP-1 receptor agonists (Ozempic, Wegovy, Mounjaro, Zepbound) has correlated with a 2% reduction in the US adult obesity rate between 2022 and 2025. This impact is reinforced by ongoing Phase ... -
Viking Therapeutics Initiates Phase 2 VENTURE-Oral Trial for Oral Dual GLP-1/GIP Agonist VK2735 in Obesity
Superpower USA Overview Viking Therapeutics has commenced its Phase 2 VENTURE-Oral trial in early 2025 for VK2735, an oral dual GLP-1/GIP receptor agonist targeting obesity. This move highlights the intense competition in the metabolic d... -
Hanmi Pharm Enters $2.3 Billion Licensing Agreement with Genentech for Global Development and Commercialization of Novel GLP-1-Independent Obesity Candidate HM17321
Pharmaceutical Executive Daily Global Overview Hanmi Pharm has signed an exclusive, global licensing agreement with Genentech, a Roche Group member, for the worldwide development, manufacturing, and commercialization of HM17321, a novel ... -
GLP-1 Receptor Agonist Mechanism of Action: A Comprehensive Approach to Glycemic Control, Weight Loss, and Metabolic Health
(Document via Google Search) Overview GLP-1 Receptor Agonists (GLP-1 RAs) are a class of drugs that mimic incretin action to manage blood sugar and promote weight loss. They stimulate insulin secretion, suppress glucagon production, and ...
